Industry Supported Session Programmes

Industry Supported Session Programmes

ROTAVIRUS AND PNEUMOCOCCAL PREVENTION: DEBATING THE CONTROVERSIES

GSK

SYMPOSIUM IS ORGANISED AND SUPPORTED BY GSK

Tuesday, May 07| 13:45 – 15:15 | Kocka Hall
Chair: Dr Volker Vetter (Belgium)

13:45–13:55

INTRODUCTION
Dr Volker Vetter, Director Global Medical Affairs, GSK (Belgium)

13:55–14:25

DEBATING RV PREVENTION RELATED CONTROVERSIES
Dr. Susanna Esposito, Director of Pediatric Clinic, Full Professor of Pediatrics at Università degli Studi di Perugia, (Italy)

Dr. Marco Safadi, Pediatric Infectious Diseases Specialist at Sabara Children’s Hospital, Head of Pediatric Department at Santa Casa Medicine School of Sao Paulo, (Brazil)

Dr. Patricia Bruijning-Verhagen, Peditrician & Epidemiologist, Associate Professor of Infectious Diseases Epidemiology & Vaccine Preventable Diseases at University Medical Center Utrecht, (The Netherlands)

Dr. Hanna Nohynek, Chief Physician, Debuty Head Unit Infectious Disease Control & Vaccines at National Institute of Health and Welfare THL Helsinki, (Finland)

14:25–15:05

DEBATING PCV PREVENTION RELATED CONTROVERSIES
All

15:05–15:15

CONCLUSION
Dr Volker Vetter, Director Global Medical Affairs, GSK (Belgium)

FOCUS ON PASSIVE IMMUNIZATION AGAINST RSV: WHERE ARE WE NOW?

SYMPOSIUM IS ORGANISED BY:
The symposium timeslot has been offered by MedImmune/ Sanofi Pasteur to the Division of Pediatrics and Neonatology, Degli infermi Hospital, Biella, Italy. Agenda and content of presentations have been developed independently by the Division of Pediatrics and Neonatology, Degli infermi Hospital, Biella, Italy, with no input from MedImmune/Sanofi Pasteur.

 

Friday, May 10| 14:00 – 15:30 | Kocka Hall
Chair: Paolo Manzoni (Italy)

14:00–14:05

WELCOME AND OPENING REMARKS
Paolo Manzoni (Italy)

14:05–14:25

TWENTY YEARS OF PALIVIZUMAB: A STATE-OF-THE-ART REVIEW ABOUT EFFICACY, BENEFITS, GAPS AND UNMET NEEDS
Bernhard Resch (Austria)

14:25–14:45

NEW GENERATION MONOCLONALS AGAINST RSV: GOING BEYOND PALIVIZUMAB
Octavio Ramilo (USA)

14:45–15:10

RESULTS FROM THE PHASE 2B RCT OF MEDI-8897, A NEW MONOCLONAL AGAINST RSV – WILL A NEW APPROACH TO PREVENTION BE POSSIBLE?
Paolo Manzoni (Italy)

15:10–15:30

PLENARY DISCUSSION & CLOSING REMARKS
Paolo Manzoni (Italy)

INNOVATING PATIENT PATHWAYS USING RAPID, ON DEMAND PCR DIAGNOSTICS

cepheid

SYMPOSIUM IS ORGANISED BY Cepheid

Monday, May 06| 10:40 – 12:15 | Kocka Hall
Chair: James Cottam (UK)

10:40–11:15

TB: STILL A DIAGNOSTIC CHALLENGE?
Dr. Marc Tebruegge, Senior Lecturer at the GOS Institute of Child Health, University College London (UK)

11:15–11:45

POINT OF CARE TESTING FOR FLU/RSV: A UK PILOT STUDY
Dr. John Boyes, Consultant medical microbiology, Gloucestershire hospitals, NHS Foundation Trust (UK)

 

11:45–12:15

EARLY RAPID DIAGNOSIS IS VITAL IN THE COMING ERA OF ANTIVIRALS AND VACCINES
Prof. Peter JM Openshaw  FRCP PhD FRSB FMedSci, National Heart & Lung Institute, Imperial College London (St. Mary’s Campus) (UK)

TICK-BORNE ENCEPHALITIS: EXPLORING THE CURRENT LANDSCAPE

pfizer_logo

SYMPOSIUM IS ORGANISED BY Pfizer

Monday, May 06 | 18:30 – 20:00 | Kocka Hall
Co-Chairs: Prof Dace Zavadska (Latvia) and Dr Wilhelm Erber (Austria)

18:30–18:35

WELCOME AND INTRODUCTION
Dr Wilhelm Erber, Director Medical and Scientific Affairs, Global Vaccines, Pfizer (Austria) and  Prof Dace Zavadska, Department of Paediatrics, Riga Stradins University (Latvia)

18:35–19:00

TBE: MAPPING THE RISK
Prof Dace Zavadska (Latvia)

19:00–19:25

TBE: A NEGLECTED TOPIC IN CHILDREN
Prof Robert Steffen, Epidemiology, Biostatistics and Prevention Institute, WHO Collaborating Centre for Travellers’ Health, University of Zurich (Switzerland)

19:25–19:50

TBE: AN UPDATED PERSPECTIVE
Dr Gerhard Dobler, Head of the Department of Virology and Rickettsiology at the Institute of Microbiology, Bundeswehr, Munich (Germany)

19:50–20:00

Q&A
Dr Wilhelm Erber (Austria)

THE ABCWY OF MENINGOCOCCAL VACCINES

pfizer_logo

SYMPOSIUM IS ORGANISED BY Pfizer

Tuesday, May 07 | 11:30 – 13:00 | Kocka Hall
Chair: Dr Jamie Findlow (Pfizer)

11:30–11:35

WELCOME AND INTRODUCTION
Dr Jamie Findlow (Pfizer)

11:35–12:00

IS THE UNPREDICTABILITY OF MENINGOCOCCAL DISEASE PREDICTABLE?
Prof Paula Mölling, Molecular biologist, University Hospital Örebro (Sweden)

12:00–12:25

COMBATTING THE HYPERVIRULENT MENW CC11 CLONE: LESSONS LEARNT FROM THE SUCCESSFUL UK IMPLEMENTATION OF MENACWY VACCINE
Dr Shamez Ladhani, Paediatric infectious disease consultant, St. George’s
Hospital (UK)

12:25–12:50

THE ABILITY OF MENB-FHBP TO PROVIDE BROAD MEN B COVERAGE
Dr Laura York, Independent consultant (USA)

12:50–13:00

PANEL DISCUSSION
All

13:00

CLOSE
Dr Jamie Findlow (Pfizer)

PNEUMOCOCCAL CONJUGATE VACCINES - EXAMINING THE EVIDENCE

pfizer_logo

SYMPOSIUM IS ORGANISED BY Pfizer

Monday, May 06 | 16:45 – 18:15 | Kocka Hall
Chair: Marko Pokorn (Slovenia), Heinz-Josef Schmitt (Pfizer, US)

16:45–16:50

WELCOME AND INTRODUCTION
Heinz-Josef Schmitt (Pfizer, US)

16:50–17:00

PNEUMOCOCCAL DISEASE IN SLOVENIA
Marko Pokorn (Slovenia)

17:00–18:00

PANEL DISCUSSION – EXAMINING THE EVIDENCE
Heinz-Josef Schmitt (Pfizer, US), Marko Pokorn (Slovenia), Ron Dagan (Israel), Robert Cohen (France), Naim Ouldali (France), Shalom Ben-Shimol (Israel)   

18:00–18:15

Q&A
All

PEDIATRIC VACCINE IN AN EVOLVING LANDSCAPE

msd

SYMPOSIUM IS ORGANISED BY MSD

Monday, May 06| 14:45 – 16:15 | Kocka Hall
Chair: Federico Martinon-Torres (Spain)

14:45–14:50

WELCOME AND INTRODUCTION
Federico Martinon-Torres, Hospital Clínico Universitario de Santiago (Spain)

14:50–15:15

WHERE ARE WE AND WHERE ARE WE GOING WITH
PNEUMOCOCCAL VACCINATION IN CHILDREN?
Richard Malley, Boston Children’s Hospital (USA)

15:15–15:35

HEXAVALENT VACCINATION IN THE YEAR 2019
Johannes Huebner, Klinikum der Ludwig- Maximilians-Universität (Germany)

15:35–16:00

CAN VACCINE MAGIC CONVERT VACCINE SKEPTICS?
Federico Martinon-Torres, Hospital Clínico Universitario de Santiago (Spain)

16:00–16:15

Q&A and Closing Remarks
Federico Martinon-Torres, Hospital Clínico Universitario de Santiago (Spain)

ELIMINATION OF HPV RELATED CANCERS AND DISEASES: DO WE HAVE ALL THE TOOLS?

msd

SYMPOSIUM IS ORGANISED BY MSD

Tuesday, May 07| 09:30 – 11:00 | Kocka Hall
Chair: Anna Giuliano (USA)

09:30–09:42

OPENING AND WELCOME MAXIMIZING THE POTENTIAL FOR ELIMINATION OF HPV CANCERS & DISEASES
Anna Giuliano, Dorothea Bennett Memorial –American Cancer Society (ACS)Clinical Research Professor Director, Center for Immunization and Infection Research in Cancer (CIIRC)Moffitt Cancer Center (USA)

09:42–09:54

HPV IN MALES: RATIONAL FOR GENDER NEUTRAL VACCINATION
Anna Giuliano (USA)

09:54–10:06

UNCOVERING THE POTENTIAL FOR HPV VACCINATION IN THE REAL WORLD
Paolo Bonanni, Full Professor of Hygiene and Public Health Department of Health Sciences University of Florence (Italy)

10:06–10:18

VACCINE CONFIDENCE IN TODAY’S WORLD
Pierre Van Damme, Full Professor University of Antwerp Director of the Centre for the Evaluation of Vaccination (CEV) Vice-Dean of the Faculty of Medicine and Health Sciences Antwerp (Belgium)

10:18–10:45

PANEL DISCUSSION
All

10:45–11:00

Q&A SESSION
All

VACCINES FOR PERTUSSIS PREVENTION: BENEFITS AND CHALLENGES

sanofi

SYMPOSIUM IS ORGANISED BY Sanofi Pasteur

Monday, May 06| 13:00 – 14:30 | Kocka Hall
Chair: Prof Ulrich Heininger (Switzerland)

13:00–13:10

WELCOME AND INTRODUCTION: WHAT IS THE RATIONALE FOR A LIFELONG APPROACH TO PERTUSSIS VACCINATION?
Prof Ulrich Heininger (Switzerland)

13:10–14:15

AN INTERACTIVE DISCUSSION

COUNTRY PERSPECTIVES ON PERTUSSIS VACCINATION IN PREGNANCY
Dr Elke Leuridan (Belgium) and Prof Goran Tešović (Croatia)

HOW CAN WE OPTIMISE VACCINE-INDUCED PROTECTION AGAINST PERTUSSIS?
Dr Emmanuel Vidor (France)

WHEN IS THE RIGHT TIME FOR PERTUSSIS VACCINATION?
Dr José Navarro (Spain)

14:15–14:25

Q&A: A CHANCE TO SHARE YOUR PERSPECTIVE
Prof Ulrich Heininger (Switzerland)

14:25–14:30

CLOSE: OPTIMISING USE OF VACCINES TO CONTROL PERTUSSIS
All

DEFEATING MENINGITIS BY 2030

SYMPOSIUM IS ORGANISED BY:

The symposium timeslot has been offered by Sanofi Pasteur to the Meningitis Research Foundation (MRF) and the Confederation of Meningitis Organisations (CoMO). Agenda and content of presentations have been developed independently by the Meningitis Research Foundation (MRF) and the Confederation of Meningitis Organisations (CoMO), with no input from  Sanofi Pasteur.

Tuesday, May 07| 08:00 – 09:15 | Kocka Hall
Chair:
Dr Kirsty Le Doare, St George’s University of London and Mulago Hospital, Kampala Uganda

08:00–08:15

THE WHO DEFEATING MENINGITIS BY 2030 GLOBAL ROADMAP
Linda Glennie, Meningitis Research Foundation United Kingdom

08:15–08:30

THE GLOBAL BURDEN OF MENINGITIS AND THE MENINGITIS PROGRESS TRACKER
Claire Wright, Meningitis Research Foundation, United Kingdom

 

08:30–08:45

ADVOCACY AND ENGAGEMENT IN THE GLOBAL PLAN AND THE ROLE OF PATIENT GROUPS
Sam Nye, Confederation of Meningitis Organisations United Kingdom

 

08:45–09:15

PANEL DISCUSSION: DEFEATING MENINGITIS BY 2030 – PERSPECTIVES OF PAEDIATRICIANS AND PATIENT REPRESENTATIVES
Chair – Dr Kirsty Le Doare, St George’s University of London and Mulago Hospital, Kampala Uganda
Panelists – Wilma Witkamp, Nederlandse Meningitis Stichting, Netherlands, Elena Moya, Asociación Española Contra la Meningitis Spain, Dr Manish Sadarangani, BC Children’s Hospital, Canada, Dr Jethro Herberg, Imperial College London